1. Home
  2. ALT vs NLOP Comparison

ALT vs NLOP Comparison

Compare ALT & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • NLOP
  • Stock Information
  • Founded
  • ALT 1997
  • NLOP N/A
  • Country
  • ALT United States
  • NLOP United States
  • Employees
  • ALT N/A
  • NLOP N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • NLOP
  • Sector
  • ALT Health Care
  • NLOP
  • Exchange
  • ALT Nasdaq
  • NLOP Nasdaq
  • Market Cap
  • ALT 397.4M
  • NLOP 474.6M
  • IPO Year
  • ALT N/A
  • NLOP N/A
  • Fundamental
  • Price
  • ALT $4.16
  • NLOP $33.71
  • Analyst Decision
  • ALT Strong Buy
  • NLOP Strong Buy
  • Analyst Count
  • ALT 6
  • NLOP 1
  • Target Price
  • ALT $18.20
  • NLOP $46.00
  • AVG Volume (30 Days)
  • ALT 11.4M
  • NLOP 77.5K
  • Earning Date
  • ALT 08-07-2025
  • NLOP 01-01-0001
  • Dividend Yield
  • ALT N/A
  • NLOP 1.01%
  • EPS Growth
  • ALT N/A
  • NLOP N/A
  • EPS
  • ALT N/A
  • NLOP N/A
  • Revenue
  • ALT $20,000.00
  • NLOP $127,453,000.00
  • Revenue This Year
  • ALT N/A
  • NLOP N/A
  • Revenue Next Year
  • ALT $1,557,547.90
  • NLOP N/A
  • P/E Ratio
  • ALT N/A
  • NLOP N/A
  • Revenue Growth
  • ALT N/A
  • NLOP N/A
  • 52 Week Low
  • ALT $2.90
  • NLOP $25.47
  • 52 Week High
  • ALT $11.16
  • NLOP $34.57
  • Technical
  • Relative Strength Index (RSI)
  • ALT 40.54
  • NLOP 64.98
  • Support Level
  • ALT $4.07
  • NLOP $32.19
  • Resistance Level
  • ALT $4.79
  • NLOP $33.01
  • Average True Range (ATR)
  • ALT 0.45
  • NLOP 0.60
  • MACD
  • ALT -0.10
  • NLOP 0.04
  • Stochastic Oscillator
  • ALT 28.16
  • NLOP 65.30

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

Share on Social Networks: